Global Medical Directory is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Connect with this vendor - Learn about this product

LiquidBiopsy Platform and Workflow

The LiquidBiopsy Workflow

By optimizing each step of the workflow, from blood collection, to circulating tumor cell (CTC) isolation and enumeration, to library prep and sequencing with Ion Torrent technology, the LiquidBiopsy platform enables you to accurately profile mutations of interest for clinical research.

Comprehensive two-day workflow from blood sample to variant data

The LiquidBiopsy Platform is part of a comprehensive, two-day workflow that enables genomic research reporting data on CTCs and cell-free DNA (cfDNA) from a single blood sample. The LiquidBiopsy instrument automates isolation of CTCs from blood samples. DNA from isolated cells and isolated cfDNA are pooled with DNA from germline white blood cells on a single chip and sequenced on an Ion Torrent™ sequencer. Resulting data may be analyzed using Ion Reporter™ Software.

The LiquidBiopsy Workflow enables the isolation of CTCs and molecular characterization of cfDNA and CTC DNA from a single blood sample. This research workflow may impact therapy response and recurrence in the future.

The LiquidBiopsy Platform automates flow cell priming, blood sample loading, target cell isolation, and immunofluoresence labeling of captured cells on the flow chip. Achieving high target cell recovery and exceptional purity, the platform enables both enumeration and downstream molecular characterization of rare cells.

Along with the Ion Torrent sequencer, it offers a comprehensive, cost-effective, sample-to-sequence workflow.

It is uniquely suited to low-input DNA sequencing without the need for whole-genome amplification.

It enables highly multiplexed analyses on serially collected archived blood samples.

It achieves <1% limit of detection critical to clinical research.

It offers rapid turnaround time; the sample-to-variant data workflow is typically completed in 2 days.